Shanghai Hile Bio-Technology Co., Ltd.

Shanghai Stock Exchange 603718.SS

Shanghai Hile Bio-Technology Co., Ltd. Operating Cash Flow for the year ending December 31, 2023: USD -1.18 M

Shanghai Hile Bio-Technology Co., Ltd. Operating Cash Flow is USD -1.18 M for the year ending December 31, 2023, a -102.78% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Shanghai Hile Bio-Technology Co., Ltd. Operating Cash Flow for the year ending December 31, 2022 was USD 42.44 M, a 518.10% change year over year.
Shanghai Hile Bio-Technology Co., Ltd. Operating Cash Flow for the year ending December 31, 2021 was USD 6.87 M, a -73.27% change year over year.
Shanghai Hile Bio-Technology Co., Ltd. Operating Cash Flow for the year ending December 31, 2020 was USD 25.69 M, a 201.92% change year over year.
Shanghai Hile Bio-Technology Co., Ltd. Operating Cash Flow for the year ending December 31, 2019 was USD 8.51 M, a 209.33% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

Shanghai Stock Exchange: 603718.SS

Shanghai Hile Bio-Technology Co., Ltd.

CEO	Ms. Qun Lin
IPO Date	May 15, 2015
Location	China
Headquarters	Economic Development Zone
Employees	295
Sector	Health Care
Industries Vaccines Biotechnology Pharmaceuticals

Description

Shanghai Hile Bio-Technology Co., Ltd. researches, develops, produces, and sells veterinary biological products for livestock and poultry in China. The company offers swine fever live vaccines; trivalent inactivated vaccines for piglets; inactivated vaccine for streptococcus suis; pseudorabies live vaccines; inactivated oil emulsion vaccine of porcine parvovirus disease; pathogenic porcine reproductive and respiratory syndrome live vaccines; transmissible gastroenteritis, porcine epidemic diarrhea, and porcine rotavirus triple live vaccines; porcine reproductive and respiratory syndrome live vaccines; swine transmissible gastroenteritis and swine epidemic diarrhea combined inactivated vaccines; porcine circovirus type 2 inactivated vaccines; and swine Japanese encephalitis live vaccines. It also provides chicken infectious bursal disease live vaccines; inactivated avian infectious rhinitis vaccines; newcastle disease and avian influenza combined inactivated vaccines; newcastle disease, infectious bronchitis, egg drop syndrome, and avian influenza quadruple inactivated vaccines; avian influenza inactivated vaccines; newcastle disease, infectious bronchitis, and avian influenza triple inactivated vaccines; avian infectious bronchitis live vaccines; avian newcastle disease and avian infectious bronchitis combined live vaccines; newcastle disease low virulent live vaccines; Marek's disease turkey herpes virus live vaccines; and fowlpox live vaccines. The company was founded in 1981 and is based in Shanghai, China.

Key trends

Past 5 years